Spero Therapeutics Inc (SPRO)

Jun 17, 2025

Complicated Urinary Tract Infection Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025

Jun 12, 2025

SPRO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jun 12, 2025

Jun 11, 2025

Spero TherapeuticsAdditional Upside Potential Following Positive Phase 3 Results (SPRO) - Seeking Alpha

Jun 11, 2025

Jun 11, 2025

Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 11, 2025

Jun 09, 2025

Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN

Jun 09, 2025

Jun 09, 2025

Jane Street Group LLC Takes Position in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 09, 2025

Jun 06, 2025

Spero Therapeutics Inc (SPRO) Is A Good Stock To Invest In - Stocksregister

Jun 06, 2025

Jun 06, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial Corp - Defense World

Jun 06, 2025

Jun 06, 2025

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled - MSN

Jun 06, 2025

Jun 04, 2025

Northern Trust Corp Sells 25,050 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 04, 2025

May 31, 2025

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week - Insider Monkey

May 31, 2025

May 31, 2025

Spero Therapeutics stock hits 52-week high at $2.53 By Investing.com - Investing.com South Africa

May 31, 2025

May 30, 2025

Spero Therapeutics stock hits 52-week high at $2.53 - Investing.com India

May 30, 2025

May 30, 2025

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - MSN

May 30, 2025

May 30, 2025

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - MSN

May 30, 2025

May 29, 2025

Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data - The Globe and Mail

May 29, 2025

May 29, 2025

Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

May 29, 2025

May 29, 2025

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr - The Pharma Letter

May 29, 2025

May 28, 2025

Biotech Finds Mid-Week Success After Meeting Primary Endpoint - The Globe and Mail

May 28, 2025

May 28, 2025

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data - insights.citeline.com

May 28, 2025

May 28, 2025

Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results - MSN

May 28, 2025

May 28, 2025

Spero Therapeutics (SPRO) Stock Explodes: Shares Skyrocket Over 200% in Stunning Midday Rally! - Daily Chhattisgarh News

May 28, 2025

May 28, 2025

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga

May 28, 2025

May 28, 2025

GSK, Spero stop UTI drug trial after early success - Reuters

May 28, 2025

May 28, 2025

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled By Stocktwits - Investing.com India

May 28, 2025

May 28, 2025

Spero Therapeutics (SPRO) Soars 255% on Phase 3 Success - GuruFocus

May 28, 2025

May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025

May 28, 2025

Spero Therapeutics stock soars on positive phase 3 trial results By Investing.com - Investing.com Nigeria

May 28, 2025

May 28, 2025

Spero Therapeutics stock soars on positive phase 3 trial results - Investing.com Australia

May 28, 2025

May 28, 2025

Spero Therapeutics’ Phase 3 Trial Meets Primary Endpoint - TipRanks

May 28, 2025

May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study - GlobeNewswire

May 28, 2025

May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee | SPRO Stock News - GuruFocus

May 28, 2025

May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - Yahoo Finance

May 28, 2025

May 17, 2025

Analyzing Perrigo (NYSE:PRGO) & Spero Therapeutics (NASDAQ:SPRO) - Defense World

May 17, 2025

May 15, 2025

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 15, 2025

May 14, 2025

Spero Therapeutics (SPRO) to Release Earnings on Wednesday - Defense World

May 14, 2025

May 13, 2025

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update - GlobeNewswire

May 13, 2025

May 13, 2025

Spero Therapeutics Advances Phase 3 Trial With Strong Cash Position, Welcomes New CEO - Stock Titan

May 13, 2025

May 13, 2025

SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq

May 13, 2025

May 13, 2025

Spero Therapeutics Inc (SPRO) Q1 2025: Everything You Need To Kn - GuruFocus

May 13, 2025

May 07, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Bought by JPMorgan Chase & Co. - Defense World

May 07, 2025

May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - The Manila Times

May 05, 2025

May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire

May 05, 2025

May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ... - Eagle-Tribune

May 05, 2025

May 03, 2025

SPROSpero Therapeuti Latest Stock News & Market Updates - Stock Titan

May 03, 2025

Apr 30, 2025

Renaissance Technologies LLC Increases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 30, 2025